Levobetaxolol

From Self-sufficiency
Revision as of 10:51, 14 April 2010 by Uanfala (Talk) (Repairing link to disambiguation page)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Levobetaxolol
File:Levobetaxolol structure.svg
File:Levobetaxolol-fill.png
Systematic (IUPAC) name
(S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
topical (ophthalmic)
Pharmacokinetic data
Biological half-life 20 hours
Identifiers
CAS Number 93221-48-8
ATC code none
PubChem CID 60657
Chemical data
Formula C18H29NO3
Molar mass 307.427 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% ophthalmic solution of levobetxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Effect

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.

The drug has been associated with bradycardia and hypertension.